MedinCell Announces Participation in Jefferies London Healthcare Conference 2022, November 15-17 in London
Euronext: MEDCL Montpellier – France November 8, 2022 – 6:00 p.m. CET
The conference will be an opportunity to introduce investors to recent and upcoming news from MedinCell, including:
• New filing of the marketing application for Uzedy™ by its partner Teva, which has confirmed that it plans to market it in the United States in the first half of 2023
• Launch by Teva of Phase 3 activities in the United States of a second treatment, mdc-TJK
• MedinCell’s partner Arthitris Innovation Corporation (AIC) launches Phase 3 activities of F14/mdc-CWM, the first localized treatment aimed at relieving pain for several weeks after total knee arthroplasty
• Advances in the experimental product portfolio at the formulation and preclinical stages